Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...

BioNTech will pay up to $150 million in additional milestones, bringing the potential total to nearly $1 billion. Analysts ...

去年11月，BioNTech和普米斯生物联合开发了一款名为BNT327的“双特异性抗体”药物。BioNTech后来预付了5500万美元，并承诺支付高达10亿美元的里程碑付款，以确保大中华区以外的权益。

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

And, in non-small cell lung cancer with specific EGFR mutations, MI Cancer Seek can be used with approved tyrosine kinase ...

That is, the point at which a drug loses patent protection and will have to compete with biosimilar competition. For Merck, ...

s Keytruda. BioNTech secured a leading candidate in the race one year ago by paying Biotheus $55 million upfront for the ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...